1stOncology™: Cancer Intelligence Service – Page 11361 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Oncology Venture calls second investment tranche under its share subscription agreement and issues 5,980,020 shares to Global Corporate Finance

On August 21, 2020 Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) ("OV" or the "Company") reported that it has called upon Global Corporate Finance (GCF) to invest in the Company in a directed share issue in accordance with the Company’s share subscription agreement with GCF (Press release, Oncology Venture, AUG 21, 2020, View Source [SID1234563940]). A total of 5,980,020 shares at a price per share of SEK 1.3420441 is issued to Global Corporate Finance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The share price is fixed at SEK 1.3420441 per share of nominal DKK 0.05 share and has been calculated as 95% of the daily volume weighted average price (VWAP) of the Company’s shares for the five (5) consecutive trading days following 11 August 2020, the date of the draw down notice from OV.

The registered share capital of Oncology Venture will after the conversion be nominal DKK 9,587,717.55 divided into 191,754,351 shares of nominal DKK 0.05 each.

The investment is the second investment tranche Oncology Venture has requested from Global Corporate Finance (New York City, NY, U.S.). Oncology Venture may call upon up to a total investment of SEK 50 million in a series of tranches, no single tranche may exceed SEK 10 million.

For further information on the conditions and structure of the financing agreement; please, refer to the press release concerning the agreement published by Oncology Venture on May 6, 2020.

Kintara Therapeutics Announces Additional $2.4 Million Private Placement Priced At-The-Market

On August 21, 2020 Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) reported that it has entered into definitive agreements with investors providing for the sale and issuance of up to 2,435 shares of its Series C Convertible Preferred Stock (the "Preferred Stock") at a purchase price of $1,000 per share in a private placement offering priced at-the-market under the rules of the Nasdaq Stock Market (Press release, Kintara Therapeutics, AUG 21, 2020, View Source [SID1234563939]). The Preferred Stock is convertible into shares of Kintara common stock at a conversion price of $1.214 per share. The offering is expected to result in gross proceeds to Kintara of up to approximately $2.4 million which is in addition to the $19.6 million previously announced. The Preferred Stock accrues dividends as previously announced.

The private placement is expected to close on or about August 24, 2020, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering for the previously announced registration study for VAL-083 in newly diagnosed and recurrent glioblastoma multiforme (GBM), the 15-patient REM-001 confirmatory lead-in study intended to continue seamlessly into a full Phase 3 pivotal study for Cutaneous Metastatic Breast Cancer (CMBC), and for working capital. Also, as previously disclosed, the GBM trial will be executed through the Company’s partnership with Global Coalition for Adaptive Research (GCAR) through the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study, an adaptive clinical trial platform in GBM.

The shares of Preferred Stock described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "Act"), and, along with the common shares issuable upon their exercise or payable as dividends pursuant to the Preferred Stock, have not been registered under the Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Invitation to presentation of BioInvent’s second quarter report 2020 on August 27, 2020

On August 21, 2020 BioInvent International AB (OMXS: BINV) reported that it will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST, followed by an audiocast with teleconference at 5.30 p.m. CEST, hosted by Martin Welschof, CEO and members of the management team (Press release, BioInvent, AUG 21, 2020, View Source [SID1234563938]). The presentation will be held in English.

To participate, please call any of the following phone numbers from:

Webcast: View Source

Northwest Biotherapeutics Announces $5 Million Financing

On August 21, 2020 Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that the Company has completed a non-dilutive debt financing for net proceeds of another $5 million (Press release, Northwest Biotherapeutics, AUG 21, 2020, View Source [SID1234563936]).

The Company anticipates that this financing will help further build the Company’s momentum by providing resources for expansion of production capacity and for ramp up of certain readiness activities as the Company approaches the readout of topline data from its Phase III trial of DCVax-L for Glioblastoma.

The Company entered into this 21-month Note (the "Loan") on August 17, 2020 for $5,505,000 at an 8% annualized interest rate, with no payments due for the first 7 months. Prepayment of the Loan can be made at any time with a 15% prepayment penalty. If the Loan remains outstanding past month 8, it will be amortized through month 21 with monthly payments of 110% of 14 equal monthly principal payments. The note also includes a $500,000 original issue discount. The lender is Iliad Research and Trading, LP.

Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast – correction

On August 21, 2020 Nordic Nanovector ASA (OSE: NANO) reported that it will report its results for the second quarter and first half 2020 on Thursday, 27 August 2020 (Press release, Nordic Nanovector, AUG 21, 2020, View Source;correction-301116398.htm [SID1234563935]).

A presentation by the Nordic Nanovector’s senior management team will take place the same day at 8:30 am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo, Meeting Room: Vika Auditorium.

The presentation will be a live webcast, and a recording will then be available at www.nordicnanovector.com in the section: Investors & Media.

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020 from 7:00 am CEST the same day.